Launch Date
12/19/2023 at 5:00 am EST
Credit Amount
1
Credit Expires
12/19/2026
Though the overall prevalence of major depressive disorder (MDD) is estimated to be largely equivalent across racial/ethnic groups, there is a significant disparity in the rate of diagnosis of MDD for many racial/ethnic underserved communities, including Black and Hispanic groups. In addition, amongst those from these communities who do receive a diagnosis, treatment offerings are often limited, with antidepressant therapy as well as psychotherapy offered at lower rates as compared to their non-Hispanic White counterparts. Social determinants / drivers of health play an additional role in these disparate outcomes, as negative drivers of health have been associated with progression to treatment resistant depression (TRD). It is imperative that each member of the multidisciplinary care team works together to address these disparities in order to improve equity in treatment and outcomes for all patients.
In this CMEO BriefCase, expert faculty will utilize case-based learning to illustrate these pervasive disparities through the stories of two patients, Luna and Eralia, while offering strategies to address inequities in the treatment and outcomes of patients with MDD and/or TRD.
At the conclusion of this activity, learners will be able to better:
Supported by an educational grant provided by Johnson & Johnson.
Physicians specializing in psychiatry, primary care, or emergency medicine, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, psychologists, counselors, social workers, and case managers
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 1.00 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.
This application-based activity is approved for 1.00 contact hours ( 0.1 CEUs) of continuing pharmacy credit ( JA0007185-0000-23-145-H01-P ).
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 12/19/2026. PAs should only claim credit commensurate with the extent of their participation.
As a Jointly Accredited Organization, CME Outfitters, LLC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. CME Outfitters, LLC maintains responsibility for this course. Social workers completing this course receive 1.00 intermediate continuing education credits.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Peek reports no financial relationships to disclose.
Dr. Jain reports the following financial relationships:
Advisory Board: Adamas Pharmaceuticals, Inc.; Alkermes; Corium, Inc.; Eisai Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Sage Therapeutics, Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; and Usona Institute
Consultant: AbbVie Inc. (Allergan); Acadia Pharmaceuticals Inc.; Adamas Pharmaceuticals, Inc.; Alfasigma USA, Inc.; Axsome Therapeutics, Inc.; Biogen; Boehringer Ingleheim; Corium, Inc.; Cingulate; Eisai Inc.; Evidera; Impel Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Osmotica Pharmaceuticals; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Sage Therapeutics, Inc; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; and Transcend Therapeutics
Research Support: AbbVie Inc. (Allergan); Lilly; Lundbeck; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Shire Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau: AbbVie Inc. (Allergan); Alkermes; Axsome Therapeutics, Inc.; Corium, Inc.; Eisai Inc.; Indivior; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc.
The following individuals have no financial relationships to disclose:
Marlon (Tony) Graham, MD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Morgan Stockberger, MD (Planning Committee)
Jessica Whelan, DNP, APRN, FPMHNP-BC, RN-BC (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Call us at 877.CME.PROS (877.263.7767).
BC-109-121923-57